Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806134 | 0.80 | PDE10A (0.46) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL2012766 | 0.79 | ALDH1A1 (0.47) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL29133299 | 0.79 | POLB (0.47) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL8564975 | 0.79 | PDE10A (0.51) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL10651130 | 0.76 | ALDH1A1 (0.45) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL986085 | 0.75 | MEN1 (0.52) | PDE10AALDH1A1POLBL3MBTL1MEN1 | |
| SCHEMBL1092487 | 0.72 | PDE10A (0.49) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL1092129 | 0.72 | PDE10A (0.49) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL13402273 | 0.72 | L3MBTL1 (0.58) | PDE10AALDH1A1POLBL3MBTL1PAX8 | |
| SCHEMBL1092131 | 0.72 | PDE10A (0.49) | PDE10AALDH1A1POLBL3MBTL1PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7799786-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080153835-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-06-26 | — | — | US | disclosed |
| EP-1556354-B1 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-01-23 | — | — | EP | disclosed |
| US-7279493-B2 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | EURO-CELTIQUE S.A. | 2007-10-09 | — | — | US | disclosed |
| EP-1810970-A1 | Therapeutic piperazine compounds | EURO-CELTIQUE S.A. (LU) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153835-A1 | Therapeutic agents useful for treating pain | CHRM2, CHRM1, MC1R | PDE10A 1370/4885ALDH1A1 1472/4885POLB 3153/4885 |
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRM2, CHRM1, MC1R | PDE10A 1370/4885ALDH1A1 1472/4885POLB 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.